# ArriVent BioPharma, Inc. (AVBP)

> Source: Nexqual · https://nexqual.com/AVBP · data as of 2026-11-18 21:00 UTC · cite as "Nexqual, ArriVent BioPharma, Inc. (AVBP), nexqual.com/AVBP" · informational, not investment advice.

## AVBP major shareholder filing: Schedule 13D/A, Oct 8, 2026
ORBIMED ADVISORS LLC, OrbiMed Capital GP VIII LLC, OrbiMed Asia GP IV, L.P. filed a Schedule 13D/A on Oct 8, 2026, reporting up to 5.80% of the class (more than 5% owner that may seek to influence the company). Item 4, Purpose of Transaction, quoted:

> The Shares acquired by the Reporting Persons were acquired for the purpose of making an investment in the Issuer and not with the intention of acquiring control of the Issuer's business on behalf of the Reporting Persons' respective advisory clients. The Reporting Persons from time to time intend to review their investment in the Issuer on the basis of various factors, including the Issuer's business, financial condition, results of operations and prospects, general economic and industry conditions, the securities markets in general and those for the Issuer's Shares in particular, as well as other developments and other investment opportunities. Based upon such review, the Reporting Persons will take such actions in the future as the Reporting Persons may deem appropriate in light of the circumstances existing from time to time. If the Reporting Persons believe that further investment in the Issuer is attractive, whether because of the market price of Shares or otherwise, they may acquire Shares or other securities of the Issuer either in the open market or in privately negotiated transactions. Similarly, depending on market and other factors, the Reporting Persons may determine to dispose of some or all of the Shares currently owned by the Reporting Persons or otherwise acquired by the Reporting Persons either in the open market or in privately negotiated transactions. …

Source: https://www.sec.gov/Archives/edgar/data/1868279/000094787126000931/0000947871-26-000931-index.htm

## What changed for AVBP since Aug 31, 2025
The built-in knowledge of several widely used AI models ends around Aug 31, 2025. Everything below is newer, dated and sourced (as of Nov 18, 2026).

- ArriVent BioPharma, Inc. (AVBP) stock went from USD 19.12 (close of the week of Aug 25, 2025, split-adjusted) to USD 10.9, a -43.0% price change; the S&P 500 (SPY) moved +14.7% over the same period.
- Analyst actions on AVBP in the last 120 days: 12 (3 upgrades or target raises, 8 downgrades or target cuts); most recent Truist Securities, Nov 10, 2026.

**Price:** USD 10.9 (+1.96% on the day) · last close of Nov 18, 2026; US market after hours, not a live price. Prev close 10.69 · day 10.33–11.11 · 52w 10.33–35.83 · market cap $564M · NGM

## Key facts
- Analysts: Buy (mean 2.00 on a 1–5 scale) (11 analysts), mean target USD 26.2 (range 22–29).
- Total return with dividends: 1Y -46.7% vs S&P 500 +11.4%; 5Y -46.1% vs S&P 500 +66.5%.
- Latest earnings report: 2026-11-16 (next date not yet announced).
- Dividend: AVBP paid no cash dividend in the last five years.
- Short interest: 11.98% of float (as of 2026-10-30), 2.4 days to cover.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|
| Operating income | -$74.6M | -$94.3M | -$178M | -$181M |
| Net income | -$69.3M | -$80.5M | -$166M | -$169M |
| EPS (diluted) | -$32.38 | -$2.56 | -$4.32 | — |
| Cash + short-term investments | $150M | $219M | $313M | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Sep 30, 2026)
P/B 1.4x · Earnings yield -30.32%

## Analysts
Consensus Buy (mean 2.00 on a 1–5 scale), 11 analysts; mean target USD 26.2 (low 22, high 29).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-11-10 | Truist Securities | Target raised | Buy | $21 → $24 |
| 2026-10-27 | Guggenheim | Target raised | Buy | $18 → $30 |
| 2026-10-20 | B. Riley Securities | Target lowered | Buy | $45 → $29 |
| 2026-10-16 | BTIG | Reiterated | Buy | $29 |
| 2026-10-08 | HC Wainwright & Co. | Target lowered | Buy | $47 → $27 |
| 2026-10-07 | Citigroup | Target lowered | Buy | $40 → $20 |
| 2026-10-07 | Jones Trading | Target lowered | Buy | $45 → $22 |
| 2026-10-07 | Truist Securities | Target lowered | Buy | $45 → $18 |
| 2026-10-07 | Guggenheim | Target lowered | Buy | $45 → $18 |
| 2026-10-07 | BTIG | Target lowered | Buy | $42 → $29 |
| 2026-08-17 | HC Wainwright & Co. | Target raised | Buy | $44 → $47 |
| 2026-08-13 | Citigroup | Target lowered | Buy | $43 → $40 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-11-18) | 5Y (from 2024-01-22) |
|---|---|---|
| Total return | -46.7% | -46.1% |
| S&P 500 (SPY) | +11.4% | +66.5% |
| Per year | -46.7% | -19.6% |
| Volatility (annualized) | 94.0% | 65.3% |
| Max drawdown | -69.2% (Jun 2026→Nov 2026) | -69.2% (Jun 2026→Nov 2026) |

## Dividends
AVBP paid no cash dividend in the last five years.

## Short interest
5,797,018 shares sold short, 11.98% of the float, as of Oct 30, 2026 (exchange short-interest report, published about twice a month). Prior report (Sep 30, 2026): 8,451,472 shares (-31.4%). Days to cover: 2.4 (short shares ÷ average daily volume).

## Peers (Biotechnology)
CGON (CG Oncology, Inc.) USD 80 +1.34% · KOD (Kodiak Sciences Inc) USD 97.81 +1.04% · BLTE (Belite Bio, Inc) USD 156.23 -0.94% · ORKA (Oruka Therapeutics, Inc.) USD 95.74 -0.60% · IBRX (ImmunityBio, Inc.) USD 6.7 +7.03% · IMVT (Immunovant, Inc.) USD 33.17 -0.12%

## More
Full page: https://nexqual.com/AVBP · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Supply chain and relationships (SEC annual reports)

Named in AVBP's own 10-K filed 2026-03-05 (https://www.sec.gov/Archives/edgar/data/1868279/000110465926024127/avbp-20251231x10k.htm):

| Relationship | Company | Sentence in the filing |
|---|---|---|
| Supplier | WuXi | "Currently, we rely on, and have agreements with, two third-party contract manufacturers, Zhejiang Raybow Pharmaceutical Company., Ltd. (Raybow) and SynTheAll Pharmaceutical Co., Ltd. (WuXi STA) to supply the drug substan…" |
| Supplier | SynTheAll Pharmaceutical | "Currently, we rely on, and have agreements with, two third-party contract manufacturers, Zhejiang Raybow Pharmaceutical Company., Ltd. (Raybow) and SynTheAll Pharmaceutical Co., Ltd. (WuXi STA) to supply the drug substan…" |
| Supplier | Fortrea Holdings Inc. (FTRE) | "Specifically, we rely on, and intend to continue to rely on, medical institutions, clinical investigators, CROs, such as Fortrea, Inc., Icon Clinical Research Limited, and Syneos Health, LLC, and consultants to conduct n…" |
| Supplier | Icon Clinical Research | "Specifically, we rely on, and intend to continue to rely on, medical institutions, clinical investigators, CROs, such as Fortrea, Inc., Icon Clinical Research Limited, and Syneos Health, LLC, and consultants to conduct n…" |
| Supplier | Syneos Health | "Specifically, we rely on, and intend to continue to rely on, medical institutions, clinical investigators, CROs, such as Fortrea, Inc., Icon Clinical Research Limited, and Syneos Health, LLC, and consultants to conduct n…" |
| Partner | Shanghai Allist Pharmaceuticals | "The parties have appointed a joint collaboration committee, comprised of representatives from both us and Allist (the Collaboration Committee), to oversee the parties' development activities related to the Licensed Compo…" |
| Partner | Aarvik Therapeutics | "Also in 2021, we entered into a research collaboration, as amended, with Aarvik Therapeutics, Inc. (Aarvik) to leverage its proprietary multi-target, multivalent, site-specific conjugation antibody platform to discover n…" |
| Partner | Lepu Biopharma | "In January 2025, we entered into an Exclusive License Agreement (the Lepu Biopharma Agreement) with Lepu Biopharma Co. Ltd. (Lepu Biopharma) pursuant to which Lepu Biopharma granted us the right to develop and commercial…" |
| Partner | Jiangsu Alphamab Biopharmaceuticals | "Our Alphamab Antibody Drug Conjugate Collaboration" |
| Competitor | Johnson & Johnson (JNJ) | "Companies that compete with us directly on the level of commercialization or development of product candidates targeting EGFR mutation-positive NSCLC include, but are not limited to, AstraZeneca, Johnson & Johnson, Bloss…" |

## Company outlook (8-K filed 2026-11-09)

- "Cash and investments of $393.2 million as of September 30, 2026 expected to fund operations to mid-2028 NEWTOWN SQUARE, PA, November 9, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc."
- "Phase 1b dose optimization data for ARR-217 in late line colorectal cancer are expected in the first half of 2027, and ARR-217 combination data with bevacizumab as well as combination data with chemotherapy are expected in the second half of 2027. 2026 Financial Results &middot;"
- "As of September 30, 2026, the Company had cash and investments of $393.2 million, which is expected to fund operations to mid-2028. &middot;"

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-12-31) | $-0.99 | $-1.01 | +$0.02 | $0 | 10 |
| Next quarter (ends 2026-12-31) | $-0.91 | $-0.98 | +$0.07 | $3.1M | 10 |
| Current fiscal year (ends 2026-12-31) | $-3.90 | $-4.34 | +$0.44 | $5.0M | 9 |
| Next fiscal year (ends 2027-12-31) | $-3.56 | $-3.81 | +$0.25 | $6.8M | 10 |

## Options: expected move (Cboe, 15-min delayed)

| Expiration | Days | ATM IV | Expected move |
|---|---|---|---|
| 2026-11-20 | 2 | 248.3% | ±14.3% |
| 2026-12-18 | 30 | 115.6% | ±26.4% |
| 2027-01-15 | 58 | 105.4% | ±33.1% |
| 2027-04-16 | 149 | 95.5% | ±47.9% |

## Earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| Nov 9, 2026 | Quarter ended Sep 30, 2026 | −$0.81 | −$1.06 | Beat +23.6% | -1.1% |
| Aug 12, 2026 | — | — | — | — | -4.4% |
| May 11, 2026 | Quarter ended Mar 31, 2026 | −$0.96 | −$0.89 | Miss −7.9% | -1.8% |
| Mar 5, 2026 | — | — | — | — | -11.8% |
| Nov 10, 2025 | Quarter ended Sep 30, 2025 | −$0.83 | −$0.78 | Miss −6.4% | +7.4% |
| Aug 11, 2025 | — | — | — | — | -5.8% |
| May 12, 2025 | — | — | — | — | -5.2% |
| Mar 3, 2025 | — | — | — | — | -7.0% |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).

## Recent SEC filings (last 120 days)
| Filed | Form | What it says | Filing |
|---|---|---|---|
| 2026-11-09 | 10-Q | Quarterly report · period ended Sep 30, 2026 | https://www.sec.gov/Archives/edgar/data/1868279/000110465926124513/0001104659-26-124513-index.htm |
| 2026-11-09 | 8-K | Quarterly results; Director or executive officer change, or pay arrangement — “On November 6, 2026, Stuart Lutzker, M.D., Ph.D. notified the Company of his intention to retire from the position of President, Research and Development of the Company and as a director of the Company, effective as of December 1, 2026 (the "Retirement Date"). Dr. Lutzker's departure was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies, or practices. In connection with Dr. Lutzker's retirement from the Company, the Company intends to enter into a…” | https://www.sec.gov/Archives/edgar/data/1868279/000110465926124484/0001104659-26-124484-index.htm |
| 2026-11-05 | Schedule 13G/A | FMR LLC, Abigail P. Johnson: 5.8% of shares, passive 5%+ holder (amended) | https://www.sec.gov/Archives/edgar/data/1868279/000031506626002691/0000315066-26-002691-index.htm |
| 2026-10-26 | 8-K | Regulation FD disclosure; Other material event | https://www.sec.gov/Archives/edgar/data/1868279/000110465926118550/0001104659-26-118550-index.htm |
| 2026-10-19 | 8-K | Regulation FD disclosure | https://www.sec.gov/Archives/edgar/data/1868279/000110465926116736/0001104659-26-116736-index.htm |
| 2026-10-13 | Schedule 13G | Vivo Opportunity Fund Holdings, L.P., Vivo Opportunity Co-Invest, L.P.: 5.0% of shares, passive 5%+ holder | https://www.sec.gov/Archives/edgar/data/1868279/000121390026109019/0001213900-26-109019-index.htm |
| 2026-10-13 | 8-K | Regulation FD disclosure; Other material event | https://www.sec.gov/Archives/edgar/data/1868279/000110465926115161/0001104659-26-115161-index.htm |
| 2026-10-08 | Schedule 13D/A | ORBIMED ADVISORS LLC, OrbiMed Capital GP VIII LLC: 5.8% of shares, 5%+ holder that may seek to influence the company (amended) — “The Shares acquired by the Reporting Persons were acquired for the purpose of making an investment in the Issuer and not with the intention of acquiring control of the Issuer's business on behalf of the Reporting Persons' respective advisory clients. The Reporting Persons from…” | https://www.sec.gov/Archives/edgar/data/1868279/000094787126000931/0000947871-26-000931-index.htm |
| 2026-10-06 | 8-K | Regulation FD disclosure; Other material event | https://www.sec.gov/Archives/edgar/data/1868279/000110465926113898/0001104659-26-113898-index.htm |
| 2026-08-12 | 10-Q | Quarterly report · period ended Jun 30, 2026 | https://www.sec.gov/Archives/edgar/data/1868279/000110465926094902/0001104659-26-094902-index.htm |
| 2026-08-12 | 8-K | Entered a material agreement; Quarterly results — “On August 11, 2026, ArriVent BioPharma, Inc. (the "Company") entered into a Collaboration and License Agreement (the "Allist License Agreement") with Shanghai Allist Pharmaceuticals Co., Ltd. ("Allist"), a pharmaceutical company incorporated under the laws of China. Pursuant to the Allist License Agreement, the Company granted Allist an exclusive, sublicensable (through multiple tiers), royalty-bearing license under certain intellectual property owned or controlled by the Company to research, develop, manufacture,…” | https://www.sec.gov/Archives/edgar/data/1868279/000110465926094869/0001104659-26-094869-index.htm |
| 2026-07-27 | Schedule 13G/A | passive 5%+ holder (amended) | https://www.sec.gov/Archives/edgar/data/1868279/000201238326002185/0002012383-26-002185-index.htm |
Source: SEC EDGAR. Quotes are the opening words of each item as filed.
